JSON
Ameur A, Kloosterman WP, Hestand MS
Trends Biotechnol. 37 (1) 72-85 [2019-01-00; online 2018-08-13]
In the past several years, single-molecule sequencing platforms, such as those by Pacific Biosciences and Oxford Nanopore Technologies, have become available to researchers and are currently being tested for clinical applications. They offer exceptionally long reads that permit direct sequencing through regions of the genome inaccessible or difficult to analyze by short-read platforms. This includes disease-causing long repetitive elements, extreme GC content regions, and complex gene loci. Similarly, these platforms enable structural variation characterization at previously unparalleled resolution and direct detection of epigenetic marks in native DNA. Here, we review how these technologies are opening up new clinical avenues that are being applied to pathogenic microorganisms and viruses, constitutional disorders, pharmacogenomics, cancer, and more.
Bioinformatics Support for Computational Resources [Service]
NGI Uppsala (Uppsala Genome Center) [Collaborative]
National Genomics Infrastructure [Collaborative]
PubMed 30115375
DOI 10.1016/j.tibtech.2018.07.013
Crossref 10.1016/j.tibtech.2018.07.013
pii: S0167-7799(18)30204-X